Q3 2026 Humana Inc. Earnings Conference Call - HUMANA INC

Financial Performance:

• Full-year adjusted EPS outlook raised from at least $9.00 to at least $9.50.
• Individual Medicare Advantage (MA) pre-tax margin target is on track to double this year, excluding the STARs headwind.
• Cost trends for 2026 were 7-8% (lower end of guidance); 2027 cost trend expected to rise to 8-9% due to a robust health technology pipeline.
• Part D costs expected to increase 14-15% in 2027, while medical costs are expected to rise slightly higher.
• Balance sheet efficiency improved significantly: divestment of Gentiva minority interest will yield ~$900M pre-tax proceeds.
• New BlackRock joint venture is projected to reduce the GAAP debt-to-capital ratio by approximately 130 basis points in Q4.
• Benefit Incurred But Not Reported (IBNR) reserves are increasing sequentially despite seasonal shifts in pharmacy costs.

Guidance and Future Outlook:

• Projected to achieve a 3%+ MA margin by 2028, driven by a one-time STARs tailwind in 2028 and sustained top quartile performance.
• 2027 membership is anticipated to grow, with AEP (Annual Enrollment Period) performance exceeding initial expectations.
• Full-year 2028 STARs rating (BY28) exceeded top quartile goals with a member-weighted rating of 4.17; BY29 is projected to achieve top quartile performance.
• Management manages the business assuming top quartile performance, treating the excess BY28 earnings as a potential one-time tailwind for investments or shareholder returns.
• 2027 margin expansion expected to be driven by pricing initiatives, product mix improvements, and operational efficiencies, alongside the resolution of STARs headwinds.
• Investor Day update scheduled for December 10, 2026, will provide detailed quantification of 2028 targets and the utilization of the STARs tailwind.

Business Segments and Product Lines:

• Medicare Advantage (MA): 2026 membership performing in line or better than expected; recapture of members from exited plans is strong; 2027 product positioning aligns with bid expectations.
• CenterWell: Added ~147,000 members (30% YoY growth) in 2026, including the acquisition of MaxHealth; established a new partnership with BlackRock to replace the Welsh Carson JV.
• Medicaid: Footprint now spans 13 states (11 active); added 104,000 members in 2026 driven by Michigan (Heidi SNIP), Illinois (FIDI SNIP), and South Carolina dual eligibles; contracts pending in Georgia and Texas.
• Product Portfolio: Focused on simple, affordable, and predictable coverage; pricing strategy prioritized margin over volume in recent bids.
• Clinical Excellence: Significant improvements in care delivery: 663,000 more care opportunities met, 534,000 additional annual preventative visits, and early detection of breast, colorectal, and diabetes-related eye cancers.

Market and Competitive Landscape:

• AEP performance ahead of plan; new sales and recapture rates are exceeding expectations.
• Industry-wide consolidation of smaller plans is benefiting larger players like Humana due to planned exits by major competitors.
• Distribution channel partners have outperformed, driven by previous quality improvement initiatives.
• Group MA business has improved 500 basis points post-recontracting, though full benefits will materialize once STARs headwinds resolve.
• Competition in the market remains intense, but Humana believes its product positioning and broker relationships provide a competitive advantage.

Risks and Challenges:

• Cost Trends: Part D and medical costs are expected to rise in 2027, potentially compressing margins if not offset by pricing.
• STARs Volatility: Future STARs earnings are subject to competitor actions and membership mix; management is disciplined to manage costs based on top quartile assumptions despite higher potential scores.
• PCO Pressure: One specific geography in Florida faces cost pressures due to outlying facilities, though mitigation steps with payers and network management are underway.
• Regulatory Environment: Changes in the regulatory landscape could impact the size and mix of the 2028 tailwind.
• Execution Risk: Delivering on the 3% margin target by 2028 depends on the successful execution of clinical outcomes and operational transformations.

Management Commentary and Tone:

• Tone is highly confident and optimistic, characterized by phrases like "strong execution," "head of plan," and "tangible results."
• Management emphasizes "discipline" over "conservatism," focusing on long-term planning and sustainable earnings power.
• CEO Jim Recton highlighted that the strategy is "working" and moving from "on plan" to "ahead of plan."
• CFO Celeste Millay stressed balance sheet fortification and the ability to make capital allocation choices rather than being forced by constraints.
• Management is transparent about the uncertainty regarding the exact split of the 2028 STARs tailwind between investment and shareholder returns.

Analyst Questions and Answers:

• 2027 Headwinds/Tailwinds: Analysts asked about 2027 margin progression; management cited no known headwinds other than existing STARs, with tailwinds from transformation, J-CURs, and improved product pricing.
• Cost Trends: Clarified that 2027 trend (8-9%) is higher than 2026 (7-8%) due to Part D technology costs; PCO costs are being mitigated through specific market actions.
• Membership Growth: Confirmed 2027 growth is expected but will be less than 2026; exact numbers are premature due to AEP timing.
• Capital Allocation: Confirmed priority on funding insurance reserves, Medicaid, and CenterWell (organic + M&A); no immediate plan for significant share buybacks until payout ratios normalize.
• STARs Strategy: Explained the shift to managing at "top quartile" to enforce cost discipline, even if actual performance exceeds this; 30% of STARs value is shared with providers via value-based arrangements.
• Reinsurance: Reinsurance usage is expected to remain stable at current levels (approx. 10% of premiums to subsidiaries) as it is deemed more efficient than debt.
• Group MA: 500 basis point improvement is noted, but full impact will be realized in 2028 as STARs headwinds lift.

Other Key Points:

• The new BlackRock JV for CenterWell includes a buy-sell option where BlackRock can exit or Humana can acquire clinics starting in 2028.
• Humana has no pending "put options" on clinics for 2027, significantly increasing financial flexibility.
• 65,000 associates are credited with driving the improved STARs ratings and clinical outcomes.
• The company is prioritizing a "top quartile" target to ensure the sustainability of a 3% margin, rather than aiming for "top decile" which may not be maintainable.
• Dividend growth is a future priority once payout ratios normalize; current buybacks are primarily to offset dilution.